Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00781326 · ClinicalTrials.gov registry record · Phase 4

Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression

A Phase 4 study, sponsored by University of Pittsburgh.

Terminated
Registry status
Phase 4
Development phase
9
Enrollment target

NCT00781326 is a Phase 4 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 9 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00781326, a Phase 4 study, was terminated before completion, sponsored by University of Pittsburgh.

TERMINATED
Registry status
Phase 4
Development phase
9 participants
Enrollment target

Study Summary

This study will examine whether combined use of an antidepressant medication and the medication nimodipine reduces risk of depression relapse in patients with vascular depression.

Interventions

  • DRUG Placebo
  • DRUG Nimodipine

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2008-08
Est. Completion 2009-02
Phase Phase 4

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT00781326

The ClinicalTrials.gov registry entry for NCT00781326 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00781326 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00781326 about?

NCT00781326 is a clinical study titled "Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression". This study will examine whether combined use of an antidepressant medication and the medication nimodipine reduces risk of depression relapse in patients with vascular depression.

What is the current status of trial NCT00781326?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2008-08. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00781326?

The interventions under investigation include: Placebo (DRUG), Nimodipine (DRUG).

Who is sponsoring clinical trial NCT00781326?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.